

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Block Listing Application to AIM

LONDON and PHILADELPHIA - May 8, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces an application has been made to AIM for a block listing of 6,500,000 ordinary shares of 10 pence each in the Company ("Ordinary Shares"). This will be used to facilitate the admission of shares to trading following the exercise of options granted under the Group's LTIP/ESOS Scheme.

The Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company. New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.

The block listing is expected to become effective on 14 May 2025. The Company will continue to make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

At the time of this announcement, Avacta has 389,788,205 Ordinary Shares in issue. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information from Avacta Group plc, please contact:

Avacta Group plc
Michael Vinegrad, Group Communications
Director

<https://avacta.com/>

Peel Hunt (Nomad and Joint Broker)
James Steel / Chris Golden

www.peelhunt.com

Panmure Liberum (Joint Broker)
Emma Earl / Will Goode / Mark Rogers

www.panmureliberum.com

ICR Healthcare
Mary-Jane Elliott / Jessica Hodgson /
Stephanie Cuthbert

avacta@icrhealthcare.com

Investor Contact
Renee Leck
THRUST Strategic Communications

renee@thrustsc.com

Media Contact
Carly Scaduto
Carly Scaduto Consulting

Carly@carlyscadutoconsulting.com

About Avacta - <https://avacta.com/>

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent

warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION[®] peptide drug conjugates (PDC) or Affimer[®] drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ALSUPUPGAUPAUQR